Tag: hotFlash

Articles

• Foods to eat & avoid during aromatase inhibitor treatment
• Hormone replacement therapy (HRT) and breast cancer
• Impact of endocrine therapy (hormone therapy) on BC prognosis

News

09/29/13

Women with lower estrogen levels have higher HRT-related BC risk

02/06/12

Soy supplements do not reduce breast cancer risk and could be harmful

01/26/11

Intense hot flashes at menopause linked to lower breast cancer risk

Studies

• Acupuncture for hot flashes in hormone receptor‐positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials Cite
  Lu W, Giobbie‐Hurder A, Tanasijevic A, Kassis SB, Park SH, Jeong YJ, et al. Acupuncture for hot flashes in hormone receptor‐positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials. Cancer. Wiley; 2024; 10.1002/cncr.35374
• Abstract SS02-02: Hormone Replacement and Alternatives for Relief of Vasomotor Symptoms in Women at Increased Risk for Breast Cancer Cite
  Fabian C. Abstract SS02-02: Hormone Replacement and Alternatives for Relief of Vasomotor Symptoms in Women at Increased Risk for Breast Cancer. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:SS02-02-SS02-02 10.1158/1538-7445.sabcs23-ss02-02
• The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation Cite
  Gomaa S, Lopez A, Slamon R, Smith R, Lapitan E, Nightingale G, et al. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation. Supportive Care in Cancer. Springer Science and Business Media LLC; 2023; 31 10.1007/s00520-023-08170-y
• Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women Cite
  Hammarström M, Gabrielson M, Crippa A, Discacciati A, Eklund M, Lundholm C, et al. Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 129:61-71 10.1038/s41416-023-02293-z
• Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT Cite
  Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. The Journal of Clinical Endocrinology & Metabolism. The Endocrine Society; 2023; 10.1210/clinem/dgad058
• Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance? Cite
  Cathcart-Rake EJ, Ruddy KJ. Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance?. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2022; 10.1093/jnci/djac113
• Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis Cite
  Zeng E, He W, Smedby KE, Czene K. Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2022; 20:683-689.e2 10.6004/jnccn.2021.7116
• Physical activity and menopausal symptoms in women who have received menopause-inducing cancer treatments Cite
  Bailey TG, Mielke GI, Skinner TS, Anderson D, Porter-Steele J, Balaam S, et al. Physical activity and menopausal symptoms in women who have received menopause-inducing cancer treatments. Menopause. Ovid Technologies (Wolters Kluwer Health); 2020; Publish Ahead of Print 10.1097/gme.0000000000001677
• Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors Cite
  Fogel J, Rubin LH, Kilic E, Walega DR, Maki PM. Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors. Menopause. Ovid Technologies (Wolters Kluwer Health); 2020; 27:1209-1219 10.1097/gme.0000000000001608
• Nonhormonal Hot Flash Management for Breast Cancer Survivors: A Systematic Review and Network Meta-Analysis Cite
  Liu J, Nie G, Li Y, Wen Z, Lu L, Xie L, et al. Nonhormonal Hot Flash Management for Breast Cancer Survivors: A Systematic Review and Network Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. Hindawi Limited; 2020; 2020:1-13 10.1155/2020/4243175
• Changes in hot flash experiences and related factors in women with breast cancer Cite
  Li C, Lin Y, Yang T, Chen S, Chang H, Shen W, et al. Changes in hot flash experiences and related factors in women with breast cancer. Menopause. Ovid Technologies (Wolters Kluwer Health); 2020; 27:535-542 10.1097/gme.0000000000001507
• Characteristics of adverse events of endocrine therapies among older patients with breast cancer Cite
  Honma N, Makita M, Saji S, Mikami T, Ogata H, Horii R, et al. Characteristics of adverse events of endocrine therapies among older patients with breast cancer. Supportive Care in Cancer. Society for Mining, Metallurgy and Exploration Inc.; 2019; 27:3813-3822 10.1007/s00520-019-04674-8
• Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial Cite
  Atema V, van Leeuwen M, Kieffer JM, Oldenburg HS, van Beurden M, Gerritsma MA, et al. Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:809-822 10.1200/jco.18.00655
• Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up Cite
  Schmidt ME, Wiskemann J, Schneeweiss A, Potthoff K, Ulrich CM, Steindorf K. Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up. International Journal of Cancer. Wiley; 2017; 142:1148-1157 10.1002/ijc.31138
• Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial Cite
  Capriglione S, Plotti F, Montera R, Luvero D, Lopez S, Scaletta G, et al. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial. Gynecologic Oncology. Elsevier BV; 2016; 143:584-588 10.1016/j.ygyno.2016.10.006
• Effect of lavender aromatherapy on menopause hot flushing: A crossover randomized clinical trial Cite
  Kazemzadeh R, Nikjou R, Rostamnegad M, Norouzi H. Effect of lavender aromatherapy on menopause hot flushing: A crossover randomized clinical trial. Journal of the Chinese Medical Association. Ovid Technologies (Wolters Kluwer Health); 2016; 79:489-492 10.1016/j.jcma.2016.01.020
• Hot flashes in breast cancer survivors: Frequency, severity and impact Cite
  Chang H, Jotwani AC, Lai Y, Jensen MP, Syrjala KL, Fann JR, et al. Hot flashes in breast cancer survivors: Frequency, severity and impact. The Breast. Elsevier BV; 2016; 27:116-121 10.1016/j.breast.2016.02.013
• Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT) Cite
  Lesi G, Razzini G, Musti MA, Stivanello E, Petrucci C, Benedetti B, et al. Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:1795-1802 10.1200/jco.2015.63.2893
• Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions Cite
  Johns C, Seav SM, Dominick SA, Gorman JR, Li H, Natarajan L, et al. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 156:415-426 10.1007/s10549-016-3765-4
• Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial Cite
  Mao JJ, Bowman MA, Xie SX, Bruner D, DeMichele A, Farrar JT. Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:3615-3620 10.1200/jco.2015.60.9412
• Menopausal Symptoms among Breast Cancer Patients: A Potential Indicator of Favorable Prognosis Cite
  Chen Y, Dorjgochoo T, Bao P, Zheng Y, Cai H, Lu W, et al. Menopausal Symptoms among Breast Cancer Patients: A Potential Indicator of Favorable Prognosis. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e75926 10.1371/journal.pone.0075926
• Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations Cite
  L’Espérance S, Frenette S, Dionne A, Dionne J. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Supportive Care in Cancer. Springer Science and Business Media LLC; 2013; 21:1461-1474 10.1007/s00520-013-1732-8
• Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis Cite
  Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, et al. Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2013; 31:2257-2264 10.1200/jco.2012.45.3068
• Menopausal symptoms and the risk of young-onset breast cancer Cite
  Fei C, DeRoo LA, Sandler DP, Weinberg CR. Menopausal symptoms and the risk of young-onset breast cancer. European Journal of Cancer. Elsevier BV; 2013; 49:798-804 10.1016/j.ejca.2012.08.030
• Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients Cite
  Fontein D, Houtsma D, Hille E, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, et al. Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. Annals of Oncology. Elsevier BV; 2012; 23:3091-3097 10.1093/annonc/mds204
• A study of lavender and tea tree oils on postmenopausal FSH levels and hot flash severity Cite
  Cohn RD, Bornhauser C, MacManus D, Sadakane M, Read W. A study of lavender and tea tree oils on postmenopausal FSH levels and hot flash severity. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2009; 27:1516-1516 10.1200/jco.2009.27.15_suppl.1516
• Hops (Humulus lupulus) Inhibits Oxidative Estrogen Metabolism and Estrogen-Induced Malignant Transformation in Human Mammary Epithelial cells (MCF-10A) Cite
  Hemachandra LP, Madhubhani P, Chandrasena R, Esala P, Chen S, Main M, et al. Hops (Humulus lupulus) Inhibits Oxidative Estrogen Metabolism and Estrogen-Induced Malignant Transformation in Human Mammary Epithelial cells (MCF-10A). Cancer Prevention Research. American Association for Cancer Research (AACR); 2011; 5:73-81 10.1158/1940-6207.capr-11-0348
• Suspected black cohosh hepatotoxicity Cite
  Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte K, Osmers R. Suspected black cohosh hepatotoxicity. Menopause. Ovid Technologies (Wolters Kluwer Health); 2011; 18:366-375 10.1097/gme.0b013e3181fcb2a6
• Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study Cite
  Rostock M, Fischer J, Mumm A, Stammwitz U, Saller R, Bartsch HH. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study. Gynecological Endocrinology. Informa UK Limited; 2011; 27:844-848 10.3109/09513590.2010.538097
• Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms Cite
  Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms. Menopause. Ovid Technologies (Wolters Kluwer Health); 2009; 16:1156-1166 10.1097/gme.0b013e3181ace49b
• Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms Cite
  Levis S. Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms. Archives of Internal Medicine. American Medical Association (AMA); 2011; 171:1363 10.1001/archinternmed.2011.330
• Relationship between Menopausal Symptoms and Risk of Postmenopausal Breast Cancer Cite
  Huang Y, Malone KE, Cushing-Haugen KL, Daling JR, Li CI. Relationship between Menopausal Symptoms and Risk of Postmenopausal Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:379-388 10.1158/1055-9965.epi-10-0998
• Abstract B99: Hot flashes, hormone therapy, and breast cancer risk: The Women's Health Initiative Clinical Trials Cite
  Farhat GN, LaCroix A, Grady D, Chlebowski R, Vitolins M, Manson J, et al. Abstract B99: Hot flashes, hormone therapy, and breast cancer risk: The Women's Health Initiative Clinical Trials. Epidemiology and Lifestyle Factors. American Association for Cancer Research; 2010; 10.1158/1940-6207.prev-10-b99
• Abstract B10: Side effects associated with aromatase inhibitor treatment among breast cancer patients Cite
  Gallicchio LM, MacDonald R, Wood B, Rushovich E, Helzlsouer K. Abstract B10: Side effects associated with aromatase inhibitor treatment among breast cancer patients. Behavioral and Social Science. American Association for Cancer Research; 2010; 10.1158/1940-6207.prev-10-b10
• Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors Cite
  Su HI, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:205-211 10.1007/s10549-010-0802-6
• Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study Cite
  Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. BMJ; 2010; 340:c693-c693 10.1136/bmj.c693